Tendinopathy, Stress, and the HPA Axis: What the Evidence Actually Shows

Tendinopathy is persistent tendon pain and dysfunction, most commonly affecting the Achilles, patellar, rotator cuff, and common wrist extensor (lateral epicondyle) tendons. It reflects degenerative changes in the tendon's collagen matrix rather than simple inflammation, which is why it behaves differently from an acute sprain and why anti-inflammatory treatments alone often disappoint. The hypothalamic-pituitary-adrenal (HPA) axis is the neuroendocrine loop that governs the body's cortisol response to physical and psychological stress. This article asks a narrower and more useful question than "does stress cause tendinopathy": does chronic HPA activation measurably slow tendon repair, and does treating stress or sleep change outcomes when added to standard care?

Cortisol released through sustained HPA-axis activation acts directly on tenocytes, the fibroblast-like cells that maintain tendon collagen, and laboratory studies have reported reduced type-I collagen gene expression in tendon cells exposed to glucocorticoids. Observational studies in runners and in occupational cohorts with high job strain have found associations between psychological stress and tendinopathy incidence or severity, though association is not proof of causation and the specific effect sizes reported in older secondary summaries of this literature should be verified against the primary papers before being repeated as precise numbers. No published trial has directly tested a stress-reduction or sleep intervention against a load-management control in a tendinopathy population, so the clinical payoff of treating stress specifically remains unproven even though the underlying biology is plausible.

Why cortisol is relevant to tendon tissue

Tendon fibroblasts express glucocorticoid receptors and respond to circulating cortisol much as other connective tissue cells do. Acute cortisol surges, lasting minutes to a couple of hours after a stressor, are a normal and largely harmless part of physiology. The concern in tendinopathy is sustained elevation: when stress is chronic, or when sleep is repeatedly restricted, the normal diurnal cortisol rhythm flattens and average exposure rises. Cell-culture and animal studies have reported that sustained glucocorticoid exposure reduces type-I procollagen expression and impairs the ability of tenocytes to remodel damaged matrix. This is a real and mechanistically coherent pathway. It has not been demonstrated in humans that reversing chronic stress reverses this effect on a clinically meaningful timescale.

Cortisol dysregulation may also interact with pain processing. Chronic stress is associated with altered central pain sensitization in the broader chronic pain literature, which could partly explain why some patients report pain that seems disproportionate to what imaging shows. This is a plausible contributing factor, not an established, tendon-specific mechanism, and it should not be used to dismiss a patient's pain or to substitute for a proper structural assessment.

What the human evidence actually shows

Several published cohort and cross-sectional studies have reported associations between measures of psychological stress (such as the Perceived Stress Scale) or job strain and the onset or severity of Achilles tendinopathy, lateral epicondyle tendinopathy, and rotator cuff-related pain. These are observational associations, not trial evidence of a treatable causal pathway, and they are confounded by the fact that stress also affects training behavior, sleep, pain reporting, and health-seeking behavior. Older secondary sources describing precise hazard ratios or percentage risk increases for this literature could not be independently verified for this draft; any specific figure should be checked against the original paper before it is published or repeated to patients.

It is well established, separately from the stress question, that structural findings on imaging do not track closely with pain. Full-thickness rotator cuff tears and tendon thickening are common on imaging in people with no shoulder pain at all, particularly with increasing age. This mismatch is one reason clinicians increasingly treat tendinopathy as a pain and function problem to be managed with a biopsychosocial lens, rather than purely as a structural lesion to be fixed. Depression and anxiety have been associated with worse pain outcomes after musculoskeletal surgery in some studies, which is consistent with, though not proof of, a role for psychological state in recovery.

Load management is the part of the evidence base that is solid

Whatever role stress plays, it does not replace the central, well-replicated finding in tendinopathy research: tendons adapt to progressive mechanical load, and structured loading programs are the intervention with the most consistent trial support across tendon sites.

• Achilles tendinopathy: Eccentric heel-drop training (the approach popularized by Alfredson and colleagues) has been studied since the late 1990s and remains a standard first-line exercise approach. Heavy slow resistance training, using slower tempo and heavier load rather than an eccentric-only pattern, has been compared to eccentric training in randomized trials with broadly similar outcomes and has been reported to be better tolerated by some patients, particularly with insertional Achilles pain where eccentric loading can aggravate symptoms.
• Patellar tendinopathy: Decline-board squats that keep the knee flexed under load are commonly used to target the patellar tendon more directly than flat-ground squats, and small trials have found them effective for reducing pain and improving function over several months.
• Lateral epicondyle tendinopathy: Progressive resistance exercise of the wrist extensors, sometimes combined with attention to ergonomics and workload, is generally preferred over injection-based treatments as an initial approach.

Exact numeric outcomes reported in older secondary sources for these protocols (specific point improvements, response percentages) vary between the original trials and should be sourced from the primary papers rather than repeated as a single fixed figure. What is consistent across the literature is the direction of effect: structured, progressive loading outperforms rest or passive treatment for most people with tendinopathy, typically over a course of weeks to a few months, and full resolution of pain does not always coincide with normalization of tendon appearance on ultrasound.

Sleep and the anabolic window for tendon repair

Adequate sleep supports tendon healing through multiple mechanisms. Slow-wave sleep triggers growth hormone release, which stimulates IGF-1 production and promotes connective tissue building. Controlled research indicates that insufficient sleep elevates cortisol levels and disrupts the normal cortisol decline overnight; inadequate sleep has also been linked to increased pain and delayed recovery in people with musculoskeletal conditions. The Pittsburgh Sleep Quality Index and similar validated measures can efficiently identify sleep problems during clinical assessment. Cognitive behavioral therapy for insomnia (CBT-I) represents the evidence-based first-line approach for chronic insomnia, preferred over medication by sleep medicine guidelines, although specific trials in tendinopathy populations are lacking. Better sleep serves as a reasonable, low-risk complement to exercise-based treatment; however, it cannot replace loading protocols, and its isolated contribution to tendon healing remains unquantified by direct research.

Nutrition support: plausible but adjunctive

Adequate protein intake provides the amino acid substrate tenocytes need to synthesize collagen, and sports-nutrition literature commonly cites intakes in the range of roughly 1.6 to 2.2 g of protein per kilogram of body weight per day for people undergoing structured resistance training or connective-tissue repair, though the range specific to tendinopathy recovery has not been separately established in trials. Vitamin C is a required cofactor for the enzyme that cross-links collagen, and standard adult RDAs are roughly 75 to 90 mg per day; correcting a frank deficiency is reasonable, but supplementing well above the RDA has not been shown to accelerate tendinopathy recovery in clinical trials, only in small mechanistic studies of collagen synthesis markers after exercise. Omega-3 fatty acids have anti-inflammatory effects at a systemic level and are generally safe within commonly used doses, but tendon-specific clinical trial evidence for symptom improvement is limited. None of these nutritional measures replace loading exercise as the primary treatment.

Mind-body interventions: real biology, unproven tendon-specific benefit

Mindfulness-based stress reduction and acceptance and commitment therapy (ACT) have documented effects on stress physiology and on pain-related psychological outcomes such as catastrophizing and fear-avoidance in the broader chronic pain literature. It is plausible that reducing HPA activation through these approaches could shift the tenocyte environment modestly toward net collagen synthesis, consistent with the cortisol mechanism described above. This has not been tested directly in a tendinopathy trial. These interventions are reasonable to offer to patients with high perceived stress or significant pain catastrophizing, framed honestly as support for the psychological and possibly hormonal side of recovery, not as a proven tendon treatment on their own.

Procedural and off-label options for refractory cases

When several months of structured, well-supervised loading has not produced adequate improvement, clinicians sometimes consider further options. These sit at different points on the evidence and regulatory spectrum and should not be presented to patients as equivalent.

• Corticosteroid injection: Provides short-term pain relief in some patients but is known to suppress local collagen synthesis and carries a recognized risk of tendon rupture, particularly in the Achilles tendon. Most contemporary tendinopathy guidance treats corticosteroid injection as, at most, a short-term bridge to enable rehabilitation rather than a primary treatment, and repeated injections into a single tendon are generally discouraged.
• Platelet-rich plasma (PRP): An autologous injection concentrating platelet growth factors, used off-label for tendinopathy. Trial results are mixed and vary by preparation type (leukocyte-rich versus leukocyte-poor) and tendon site; some trials favor PRP over corticosteroid at longer follow-up, others show no meaningful difference from saline or exercise alone. PRP does not have an FDA-approved indication for tendinopathy, and patients should understand this is off-label use of an autologous blood product with a variable evidence base.
• Sclerosing injections (for example polidocanol): Target abnormal neovascularization seen on Doppler ultrasound in some painful tendons. Evidence is limited to a small number of older trials and this is a niche, specialist-delivered option rather than a routine treatment.
• BPC-157: A synthetic peptide studied in animal models for tendon and soft-tissue healing. It is not FDA-approved for any human indication, and the FDA has taken regulatory action limiting its use in compounded preparations because of safety concerns; the current status should be confirmed directly with FDA sources before this is discussed with a patient, since compounding regulations for peptides have changed over recent years. There is no published human randomized controlled trial evidence for BPC-157 in tendinopathy as of this writing. Any patient considering it outside of a regulated trial should understand they are using an unapproved substance with an unknown human safety and efficacy profile, and should discuss this explicitly with a physician rather than self-source it.

When to seek urgent or in-person evaluation

A sudden sharp pain with a popping sensation, inability to bear weight or push off, or a visible gap in the tendon (most concerning at the Achilles) suggests a possible tendon rupture and warrants prompt in-person evaluation rather than continued home exercise. Progressive weakness, night pain that is not mechanical, unexplained swelling, fever, or pain following a significant injury also warrant clinical assessment before starting or continuing a loading program. This article does not provide individualized diagnosis or an exercise prescription; a clinician should confirm the diagnosis and tailor load progression to the specific tendon and patient.

Evidence-status interaction assessment: stress, cortisol, and tendinopathy

What is established, what is plausible, and what is not

Established: Progressive tendon loading improves tendinopathy symptoms and function across major tendon sites. Cortisol suppresses collagen synthesis in tendon cells in laboratory conditions. Imaging abnormalities are common in people without pain, so symptoms and function should guide treatment decisions more than scan appearance. Corticosteroid injection carries a real tendon rupture risk.

Plausible but unproven in trials: That reducing chronic psychological stress or improving sleep meaningfully speeds tendinopathy recovery beyond what loading exercise alone achieves. That routine screening for stress and sleep at the first tendinopathy visit changes outcomes, even though it is inexpensive and low-risk to do.

Not established: A specific numeric effect size for how much stress or cortisol worsens human tendinopathy outcomes. Any human efficacy or safety profile for BPC-157 in tendon injury. That any single off-label injection therapy is superior to structured exercise as a first-line treatment.

Frequently asked questions

A note on this draft

This article draws on published research in tendinopathy and stress physiology for informational purposes. Detailed metrics from earlier versions of this content (specific hazard ratios, percentage effect sizes, and sample sizes from cited trials) could not be confirmed against original primary sources during this update and have been removed or made more general rather than restated with precision. Clinicians applying this information to individual patients should independently verify current clinical guidelines and, for any procedural or off-label interventions, regulatory approval directly through primary sources including PubMed and FDA resources before clinical decisions are finalized.